Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736680 | 0.82 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL27241815 | 0.81 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL29985533 | 0.81 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL27076007 | 0.81 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL29985821 | 0.81 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL23132983 | 0.77 | MAP4K1 (0.55) | MAP4K1 | |
| SCHEMBL23104851 | 0.76 | MAP4K1 (0.57) | MAP4K1 | |
| SCHEMBL23089405 | 0.75 | MAP4K1 (0.56) | MAP4K1 | |
| SCHEMBL29736347 | 0.75 | MAP4K1 (0.56) | MAP4K1 | |
| SCHEMBL27241818 | 0.71 | MAP4K1 (0.46) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| CN-117377673-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20220363695-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363695-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAP4K1 99/4885 |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, HIPK3 | MAP4K1 49/4885 |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, PGK1 | MAP4K1 56/4885 |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | PDXK, HIPK1, HIPK3 | MAP4K1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.